Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Even if Amarin prevails in its patent infringement lawsuit, its key patents on Vascepa are likely to be ruled invalid in ongoing litigation, opening the way for generic formulations.
An intensive program supplements student education and collaboration while narrowing the disconnect between rising healthcare needs and trainees with the technical expertise to tackle pandemic-related challenges.
Interest is growing in genome-editing tools that can insert large chunks of DNA into the genome — and avoid the double-strand breaks associated with CRISPR–Cas9 genotoxicity.
A survey of national R&D-driven health biotech sectors ranks Switzerland, Sweden and the United States as leading centers for R&D-driven biotech. John Hodgson and Deanna Schreiber-Gregory report.
